Redhill Biopharma
RDHL
34 hedge funds and large institutions have $41.7M invested in Redhill Biopharma in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 34 → 34 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
36% less capital invested
Capital invested by funds: $64.8M → $41.7M (-$23.1M)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$6.86M |
| 2 |
Jane Street
New York
|
+$454K |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$393K |
| 4 |
VF
Virtu Financial
New York
|
+$84.7K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$30.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$3.4M |
| 2 |
Millennium Management
New York
|
-$254K |
| 3 |
Morgan Stanley
New York
|
-$169K |
| 4 |
D.E. Shaw & Co
New York
|
-$113K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$101K |
RDHL Hedge Fund Activity: Q2 2019 in Review
34 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2019, worth a combined $41.7M — down 36% from $64.8M a quarter earlier.
Fund positioning in RDHL was balanced in Q2 2019: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 10 trimmed.
The largest buyer was Ibex Investors, adding an estimated $6.86M. The largest seller was Menora Mivtachim Holdings, exiting entirely with an estimated $3.4M sold.
- 34 institutional investors held Redhill Biopharma (RDHL) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $41.7M of Redhill Biopharma stock for Q2 2019, down 36% quarter-over-quarter.
- 4 funds opened new Redhill Biopharma positions in Q2 2019 and 4 closed out, a net change of 0 holders.
- The largest Redhill Biopharma buyer in Q2 2019 was Ibex Investors, an estimated $6.86M added.
- The largest Redhill Biopharma seller in Q2 2019 was Menora Mivtachim Holdings, an estimated $3.4M sold.
Based on aggregated 13F filings for Q2 2019.